PatientsVille.com Logo

Type and Atoris

PatientsVille

Type Symptoms and Causes

Diabetes means your blood glucose, or blood sugar, levels are too high. With Type 1 diabetes, your pancreas does not make insulin. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood. Over time, high blood glucose can lead to serious problems with your heart, eyes, kidneys, nerves, and gums and teeth.

Type 1 diabetes happens most often in children and young adults but can appear at any age. Symptoms may include

  • Being very thirsty
  • Urinating often
  • Feeling very hungry or tired
  • Losing weight without trying
  • Having sores that heal slowly
  • Having dry, itchy skin
  • Losing the feeling in your feet or having tingling in your feet
  • Having blurry eyesight

A blood test can show if you have diabetes. If you do, you will need to take insulin for the rest of your life. A blood test called the A1C can check to see how well you are managing your diabetes.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for type

type treatment research studies

Atoris clinical trials, surveys and public health registries


Find Drug Side Effect reports



Atoris Side Effects

Blood Creatinine Increased (10)
Vision Blurred (5)
Hypocapnia (3)
Liver Disorder (3)
Asthma (2)
Myositis (2)
Blood Glucose Increased (2)
Vomiting (2)
Visual Impairment (2)
Haemorrhagic Anaemia (1)
Hepatotoxicity (1)
Gastric Neoplasm (1)
Gastric Haemorrhage (1)
Bronchitis Chronic (1)
Faeces Discoloured (1)
White Blood Cell Count Increased (1)
Hypoxia (1)
Pancreatic Carcinoma (1)
Overdose (1)
Rhabdomyolysis (1)
Tumour Haemorrhage (1)
Ureteric Stenosis (1)
Abdominal Pain Upper (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Dont get discouraged, I am 21 years old and got diagnosed with diabetes when i was 15. I hated it for a little while then i thought well i have to live with it so i better make the best of it. I, just like anyone, wanted to live an ordinary teen life

I am 14 and type one diabetic, and i just want it to go away so i can live a normal happy life, i would like to drink to see what its like (typical teen) but i really dont want diabetes , so i don't really care about it, my mum and dad get worried be

I am a <b>Cancer patient with Diabetes Type 2 and dependent on Human Insulin for many years. I am on Insulin on two times a day. I was on chemotherapy several times and many cycles. My sugar level is still unconrolled.&n

I was diagnosed with type B flu Tuesday. Dr. said it was too late to treat with Tamiflu. 1st two days massive coughing fits(so much my chest hurt), headache, sore throat, tired and achey, 100.4 temp. 5 days later temperature, sore

Is frequent urination type 1 diabeetus connected in any way? I know that type 1 diabetics urinate alot or more when having high blood sugars, ok which I have had none of late. Thanks for your input.

Is it okey to give my son three kinds of vitamins a day

What happens if you take three of the the same type of vitamins at once?

Wow i am sorry to hear this. i am 44 years old and was diagnosed with type 1 diabetes at 17 years old, very late for juvenile. my brother also has had type 1 since he was 11 and he is 48 now. we live a perfectly normal life for the most. we both have

Hi! am looking Operational and Installation manual for this type of x-ray machine Summit AmeriComp control console, with power module SHF 310 and other accessories of it. Well! let me give you this control console picture may be you will aware of

I WANT FRIENDS WHO HAVE TYPE 1DIABETIC

sorry type errors if i could do it over i would have never taken this drug if i had only know .. wahtever you do don't just trust your doctor is doing the right thing or even a good thing for you like i did do

My grand father was diagnosed with dementiaalzheimer's type and was prescribed Aricept. After he started taking Aricept, his condition have gotten worse and he actually died yesterday. He was 83 years old.

<span style='color: #808080;'><b>Describe Your Henoch-Schonlein purpura from INFLUENZA (H1N1) (H1N1 (MONOVALENT) SANOFI) 2010 Experience Here:</b> Vicious headaches, rash on legs and trunk, transient, cystitis type fee

After being exposed to bright light my vision field is spotty with bright lights. I have a similar experince when I'm hypoglycemic often my first sympto but this type is unrelated to my BLOOD SUGAR. mY LATEST MEDS ADDED ARE Cardizem for A-fib, coumad

After just 7 days of starting pioglitazone(15 mg.daily) ,I developed loss of taste for mainly sugar and salt,but unfortunatyely i couldnot guess pioglitazone as possible cause. I am type 2 diabetic and hypertensive and taking metformin,glimeperide,li

After taking 500mg of fortamet for two weeks i am having blured vision . i am type 2 diabetic.

Another thing, can a patient with diabetes type 1 and previously suffered and recovered from Multiple sclerosis ( M-S ) use Spasfon ???

Asked my Cardiologist about this drug. He said I was a candidate, but said he had two patients that reacted to it. One had her lips peel off and the other had some type of negative reaction. We agreed to 'wait and see' as there just haven't been t

Type Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting STUDY IN LEUCOCYTES FROM PATIENTS WITH Type 1 AND Type 2 DIABETES GENETIC MARKERS OF INFLAMMATION AND OXIDATIVE STRESS (TÉLOMÈRES/ CANDIDATE GENES) ACCORDING TO THE Type A OR Type B BEHAVIOUR PROFILE
Conditions: Patients With Type 1 or Type 2 Diabetes;   Patients With a Type A or B Behaviour Profile
Intervention: Other: Blood sample of 12 ml
Outcome Measures: Telomere length;   Level of expression of candidate genes
2 Not yet recruiting Botulinum Toxin Type A for Neuroma Pain
Condition: Neuroma
Interventions: Drug: onabotulinum toxin Type-A;   Other: placebo;   Drug: 2nd phase - onabotulinum toxin Type-A
Outcome Measures: number of pain-free days;   quality of life;   upper extremity function;   lower extremity function;   patient satisfaction;   quality-adjusted life-years
3 Recruiting A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
Condition: Diabetes Type 2
Interventions: Drug: DM199;   Drug: Placebo
Outcome Measures: Safety and tolerability of single and multiple subcutaneous doses of DM199;   Determine the pharmacokinetic of DM199 after single and multiple doses;   Determine the effect of DM199 on glucose homeostasis in healthy volunteers and Type 2 diabetes mellitus patients;   Assess formation of ADA to DM199;   Determine changes in immune cell populations by FACS analysis.
4 Recruiting Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care
Condition: Type 2 Diabetes
Interventions: Other: Remote, personalized Type 2 diabetes care.;   Other: Usual Endocrine care.
Outcome Measures: Change in baseline A1C (glycated hemoglobin) at 12 months;   Change in baseline lipids at 12 months;   Change in baseline blood pressure at 12 months;   All cause mortality;   Acute complications;   Change in baseline Quality of life at 12 months;   Change in baseline insulin satisfaction at 12 months
5 Recruiting Natural History Study of the Development of Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Intervention:
Outcome Measures: Development of Type 1 diabetes;   Metabolic and Autoantibody Assessments
6 Recruiting Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Conditions: Inflammatory Bowel Disease;   Glycogen Storage Disease Type Ia
Intervention: Other: Glycogen Storage Disease Type Ia patients
Outcome Measure: Serologic, genetic and inflammatory markers consistent with inflammatory bowel disease
7 Unknown  Prospective Assessment in Newborns for Diabetes Autoimmunity
Conditions: Type 1 Diabetes;   Autoimmunity
Intervention:
Outcome Measures: autoantibodies against the pancreas and Type 1 diabetes;   Risk factors for Type 1 diabetes
8 Recruiting Type II Diabetes Influence on Left Ventricular Remodeling and Outcomes in Patients Undergoing Aortic Valve Replacement Surgery.
Condition: Type II Diabetes
Intervention: Other: Intervention
Outcome Measures: Left Ventricular Mass measured by echocardiography;   cardiovascular events (cardiac mortality, heart failure, atrial or ventricular rhythm abnormalities) and clinical improvement (NYHA class, 6-minute walk test).;   Measurement of BNP (Brain Natriuretic Peptide).;   Echocardiographic parameters.;   Magnetic Resonance Imaging (MRI) parameters.
9 Recruiting Evaluation of Two Self-management Oriented Diabetes Education Programs for Insulin Therapy in Type 2 Diabetes
Condition: Type 2 Diabetes
Interventions: Behavioral: MEDIAS 2 ICT;   Behavioral: Current ICT program (ACC-ICT);   Behavioral: MEDIAS 2 CT;   Behavioral: Current CT program (ACC-CT)
Outcome Measures: A1c values;   Quality of life using the SF 12 mental and physical composite scales;   diabetes knowledge (Diabetes knowledge test for insulin treatment in Type 2 diabetes);   diabetes related distress (Problem areas in Diabetes Questionnaire -PAID) and satisfaction with insulin therapy (Insulin Treatment Experience Questionnaire ITEQ);   Self care behavior (Summary of Self-Care Activities Scale);   lipids (total cholesterol, triglycerides, HDL and LDL);   weight (Body mass index)
10 Recruiting Imaging of Type 1 Diabetes Progression
Condition: Type 1 Diabetes
Intervention: Drug: ferumoxytol
Outcome Measure:
11 Unknown  Oxidative Stress Markers Evaluation Before and After Periodontal Treatment of Diabetics Type 2 Patients
Condition: Diabetes Mellitus Type 2
Interventions: Procedure: non- surgical periodontal treatment;   Procedure: Prophylaxis
Outcome Measure: Evaluate level change of oxidative stress biomarkers in crevicular gingival fluid and whole saliva on diabetes Type 2 individuals
12 Recruiting Sleep Apnea in Type 1 Diabetes
Condition: Type 1 Diabetes, Sleep Apnea Syndrome
Interventions: Other: Polysomnography;   Other: Evaluation of the autonomous nervous system;   Other: Clinical examination of the sleep;   Other: Clinical examination of diabetology;   Other: Biological dosages;   Other: Electrocardiogram (ECG);   Other: Carotid echography;   Other: Blood pressure
Outcome Measures: Compare the prevalence of sleep apnea syndrome by polysomnography between Type 1 diabetic patients and healthy volunteers;   Precise if glycemic balance as defined by glycosylated hemoglobin<7% during the last three months is associated or not to sleep apnea syndrome;   Precise if the presence of an autonomic neuropathy (positive at 2 tests) is associated or not to sleep apnea syndrome;   Compare the patients with or without sleep apnea regarding consequences especially cardiovascular markers and coagulation factors;   Determine if the presence of sleep apnea syndrome has an impact upon quality of life and diabetes complications, micro or macroangiopathy;   Precise clinical symptoms in DT1 patients with Sleep apnea syndrome
13 Recruiting Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk
Condition: Type 2 Diabetes
Interventions: Other: HbA1c measurement;   Other: Oral Glucoce Tolerance Test
Outcome Measure: Measure of risk of developing Type 2 diabetes in at-risk families
14 Recruiting Effects of Metreleptin in Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes
Intervention: Drug: Leptin ( Metreleptin )
Outcome Measures: Change in HgbA1c;   safety and tolerability of leptin in Type 1 Diabetic patients;   Mean and standard deviation of blood glucose;   change in liver and muscle fat as measured by Liver and soleus triglycerides on MRS.;   Change in Glycomark
15 Unknown  The Effects of High and Low GI Breakfasts on Cognitive Performance in Adults With Type 2 Diabetes
Condition: Type 2 Diabetes
Intervention:
Outcome Measures: Cognitive performance (e.g. memory, attention, reaction time, and problem solving ability).;   Blood glucose levels;   Subjective sensations of appetite, mood, and mental alertness;   Sleep quality;   Stress levels
16 Recruiting Periodontal Treatment Response in Type II Diabetic Patients
Conditions: Type II Diabetes;   Periodontal Disease
Interventions: Drug: Triclosan containing toothpaste;   Drug: Non-triclosan containing toothpaste
Outcome Measures: Clinical Periodontal Parameters;   Local Inflammatory Markers;   Glycemic Control;   Systemic Inflammatory Markers
17 Recruiting Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus
Conditions: Diabetic Neuropathy;   Cognitive Impairment
Interventions: Dietary Supplement: Tocotrienol;   Dietary Supplement: Placebo
Outcome Measures: Total Symptoms Score (TSS) (pain, paresthesia, burning, and numbness)of patients with diabetes Type 1 and 2 neuropathy.;   Neuropathy Impairment Score (NIS) of patients with diabetes Type 1 and 2 neuropathy
18 Not yet recruiting Arterial Stiffness and Complication Risk in Type 2 Diabetes
Conditions: Diabetes Mellitus, Type 2;   Diabetes Complications;   Diabetic Angiopathies;   Diabetic Nephropathies
Intervention:
Outcome Measures: White matter lesions (MRI);   Albuminuria;   Segment Involvement Score (CT);   Agatston Score (CT)
19 Recruiting Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus
Conditions: Type 2 Diabetes Mellitus;   Insulin Sensitivity/Resistance
Interventions: Drug: Linagliptin;   Drug: Placebo;   Drug: Voglibose
Outcome Measures: To study the effect of Linagliptin on insulin sensitivity by performing euglycemic hyperinsulinemic clamp in patients with Type 2 diabetes mellitus.;   To study the effects of Linagliptin on glycemic control and beta cell function in patients with Type 2 diabetes mellitus 6 months
20 Unknown  The Surgical Treatment of Type 2 Diabetes Mellitus in Non-Morbidly Obese Patients: A Community Hospital Study
Condition: Type 2 Diabetes Mellitus
Interventions: Procedure: Laparoscopic duodenal exclusion;   Other: Conventional Medical Treatment
Outcome Measure: Hemoglobin A1C